Symphogen A/S

Develops recombinant antibody mixtures for the treatment and prevention of disease

Transaction Summary

  • Robust pipeline with development stage candidates across multiple indications
  • Closed $70M private financing in October 2015 to continue developing pipeline
  • Results from Phase II trials in 2016 - 2017 a key milestone that could trigger an acquisition of the company
  • Strong interest from strategics could result in sale of development programs for significant up-front payment plus milestones